Datavault AI Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Datavault AI Inc. (DVLT) on August 27, 2025. The filing addresses Item 5.07 regarding the submission of matters to a vote of security holders. The Company is incorporated in Delaware and trades on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on corporate governance actions related to a prior securities purchase agreement and a waiver arrangement.
Material Changes and Corporate Actions
- Waiver Agreement: On July 21, 2025, the Company entered into a Waiver Agreement with purchasers from a March 31, 2025, securities purchase agreement. Purchasers waived variable rate transaction provisions for 60 days and participation rights.
- Sales Restrictions: In exchange for the waiver, the Company agreed not to sell common stock under its July 21, 2025, sales agreement with Maxim Group LLC if: (i) sales exceed 10% of daily trading volume, (ii) sales occur outside regular trading hours, (iii) the price is below $1.10 per share, or (iv) the aggregate amount exceeds $25,000,000.
- Share Issuance: The Company agreed to issue 5,000,000 shares of Common Stock to the Purchasers upon receiving stockholder approval.
- Stockholder Approval: On August 27, 2025, holders of 50,365,422 shares (approximately 52% of voting power) executed a Written Consent to approve the issuance of the 5,000,000 shares to comply with Nasdaq Listing Rule 5635(d).
Outlook, Risks, and Contingencies
The issuance of shares approved by the Written Consent cannot become effective earlier than 20 calendar days following the mailing of the Information Statement on Schedule 14C. The filing notes that an Information Statement will be filed with the SEC and mailed to stockholders. No specific forward-looking guidance or new risk factors were disclosed in this specific report beyond the mechanics of the waiver and share issuance.
Key Facts for Investor Verification
- Verify the effective date of the 5,000,000 share issuance following the 20-day waiting period after the Schedule 14C mailing.
- Confirm the impact of the 5,000,000 share issuance on existing shareholder dilution.
- Monitor compliance with the $1.10 price floor and volume restrictions on the Company's sales agreement with Maxim Group LLC.
- Review the full Schedule 14C Information Statement for detailed terms of the Waiver Agreement and the March 2025 Purchase Agreement.